Selected partnerships
Bayer Schering Pharma has a long-term record of successful partnerships involving both large and small companies or academic institutions. Our activities span from inlicensing deals through co-marketing or co-promotion partnerships to collaborations where we outlicensed a substance. Here are some examples of our partnerships.
| Partner | Scope |
|---|---|
| Algeta ASA | Co-development of Alpharadin™ for the treatment of bone metastases |
| Ardea Biosciences | Co-development of MEK inhibitors |
| Avid Radiopharmaceuticals | Radiopharmaceutical compounds |
| Bausch & Lomb | Selective glucocorticoid receptor Agonist (SEGRA) for treatment of eye diseases * |
| BioInvent | Antibody discovery |
| Bioton S.A. | Supply and distribution agreement for recombinant human insulin for the Chinese market |
| Boehringer Ingelheim | Co-marketing of telmisartan in Europe, a compound for management of hypertension |
| Celera Corporation | Extension of research portfolio in the area of cancer-related targets |
| Eidgenössische Technische Hochschule Zürich(ETH) |
Radiopharmaceutical compounds |
| EndoCeutics, Inc. | Development of Vaginorm for the treatment of vaginal atrophy and female sexual dysfunction |
| Genentech | Development rFVIII worldwide for treatment of hemophilia |
| Genzyme Corporation | Hematological oncology portfolio *, Co-development for alemtuzumab in multiple sclerosis |
| GlaxoSmithKline | Co-promotion of Levitra® in the US * |
| Hamamatsu Photonics | Novel molecular imaging tracers for the diagnosis of cancer |
| ImmunoGen | Antibody toxin conjugates |
| Indevus Pharmaceuticals | Development of Nebido® in the US for treatment of male hypogonadism * |
| Johnson & Johnson | Development of novel anticoagulant rivaroxaban (Xarelto®) and distribution in the US * |
| Micromet | BiTE antibody for oncology |
| Nagasaki University | Novel molecular imaging tracers for the diagnosis of Alzheimer Disease |
| Nektar Therapeutics | Development of targeted inhaled antibiotic therapy for pulmonary infections (Amikacin Inhale and Cipro Inhale) |
| OncoMed Pharmaceuticals | Discovery and development of anti-cancer stem cell therapeutics |
| Onyx Pharmaceuticals | Co-development of Nexavar® for various cancer indications |
| Pfizer | Development of DGAT-1 inhibitor for treatment of diabetes and obesity * |
| Philogen | Development of immunoconjugates for cancer therapy and diagnosis |
| Prometheus Laboratories, Inc. | Development of in-vitro diagnostic assays to enable personalized therapeutics |
| Regeneron Pharmaceuticals | Development of VEGF Trap-Eye for the treatment of eye diseases |
| Seattle Genetics | Antibody toxin conjugates |
| Schering-Plough | Distribution of Primary Care products in the US * |
| Shire | Development of Fosrenol® in Japan for treatment of hyperphosphatemia |
| Stanford University | Radiopharmaceutical compounds |
| Tsinghua University Beijing | Foundation of joint research center for collaboration in drug discovery and development |
| ZymoGenetics | Recombinant thrombin |
| * = substance/product has been outlicensed by Bayer Schering Pharma | |
- Age-related macular degeneration (AMD)
- Breast cancer
- Contraception
- Diabetes
- Endometriosis
- Erectile Dysfunction (Erection Problems)
- Gynecological therapy
- Heartattack and stroke
- Hemophilia
- High blood pressure
- Infectious diseases
- Liver Cancer
- Menopausal Complaints
- Multiple sclerosis
- Non-Hodgkin's lymphomas
- Peripheral arterial occlusive disease
- Premenstrual Dysphoric Disorder (PMDD)
- Prostate cancer
- Pulmonary arterial hypertension
- Renalcell carcinoma
- Testosterone Deficiency
- Thromboses
© 2009 Bayer Schering Pharma Imprint
